Search Results - "TANGEN, C. M"

Increased Blood Glucose and Insulin, Body Size, and Incident Colorectal Cancer by Schoen, Robert E., Tangen, Catherine M., Kuller, Lewis H., Burke, Gregory L., Cushman, Mary, Tracy, Russell P., Dobs, Adrian, Savage, Peter J.

“…BACKGROUND: Abdominal obesity—an elevated level of visceral adipose tissue—has been linked to colorectal cancer. Furthermore, elevated levels of visceral…”
Get full text

Frailty in older adults: evidence for a phenotype by Fried, L P, Tangen, C M, Walston, J, Newman, A B, Hirsch, C, Gottdiener, J, Seeman, T, Tracy, R, Kop, W J, Burke, G, McBurnie, M A

“…Frailty is considered highly prevalent in old age and to confer high risk for falls, disability, hospitalization, and mortality. Frailty has been considered…”
Get full text

Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study by Leichman, C G, Fleming, T R, Muggia, F M, Tangen, C M, Ardalan, B, Doroshow, J H, Meyers, F J, Holcombe, R F, Weiss, G R, Mangalik, A

“…A variety of fluorinated pyrimidine-based regimens for the treatment of disseminated colorectal cancer have been presented in the medical literature. The…”
Get more information

Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer by Moertel, C G, Fleming, T R, Macdonald, J S, Haller, D G, Laurie, J A, Tangen, C M, Ungerleider, J S, Emerson, W A, Tormey, D C, Glick, J H

“…To determine the effectiveness of fluorouracil plus levamisole administered postoperatively to patients with resected stage II (Dukes' B2) colon cancer. This…”
Get more information

Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer by Halabi, S, Dutta, S, Tangen, C M, Rosenthal, M, Petrylak, D P, Thompson, Jr, I M, Chi, K N, De Bono, J S, Araujo, J C, Logothetis, C, Eisenberger, M A, Quinn, D I, Fizazi, K, Morris, M J, Higano, C S, Tannock, I F, Small, E J, Kelly, W K

“…We have shown previously in multivariable analysis that black men had 19% lower risk of death than white men with metastatic castration-resistant prostate…”
Get full text

Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial by Lucia, M. Scott, Epstein, Jonathan I., Goodman, Phyllis J., Darke, Amy K., Reuter, Victor E., Civantos, Francisco, Tangen, Catherine M., Parnes, Howard L., Lippman, Scott M., La Rosa, Francisco G., Kattan, Michael W., Crawford, E. David, Ford, Leslie G., Coltman, Charles A., Thompson, Ian M.

“…Background The Prostate Cancer Prevention Trial (PCPT) reported a decreased incidence of prostate cancer overall but an increase in the incidence of high-grade…”
Get full text

Biomarkers of Systemic Inflammation and Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial by Schenk, Jeannette M., Kristal, Alan R., Neuhouser, Marian L., Tangen, Catherine M., White, Emily, Lin, Daniel W., Kratz, Mario, Thompson, Ian M.

“…The authors conducted a nested case-control study of serum inflammatory markers and risk of symptomatic benign prostatic hyperplasia (BPH), using data from the…”
Get full text

Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng ml(-1), normal DRE and negative for prostate cancer by Umbehr, M H, Gurel, B, Murtola, T J, Sutcliffe, S, Peskoe, S B, Tangen, C M, Goodman, P J, Thompson, I M, Lippman, S M, Lucia, M S, Parnes, H L, Drake, C G, Nelson, W G, De Marzo, A M, Platz, E A

“…Biopsies performed for elevated serum PSA often show inflammatory infiltrates. However, the influence of intraprostatic inflammation on serum PSA in men…”
Get full text

Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial by Bhasin, Shalender, Travison, Thomas G, Pencina, Karol M, O'Leary, Michael, Cunningham, Glenn R, Lincoff, A Michael, Nissen, Steven E, Lucia, M Scott, Preston, Mark A, Khera, Mohit, Khan, Nader, Snabes, Michael C, Li, Xue, Tangen, Catherine M, Buhr, Kevin A, Thompson, Jr, Ian M

“…The effect of testosterone replacement therapy (TRT) on the risk of prostate cancer and other adverse prostate events is unknown. To compare the effect of TRT…”
Get full text

Non-parametric covariance methods for incidence density analyses of time-to-event data from a randomized clinical trial and their complementary roles to proportional hazards regression by Tangen, Catherine M., Koch, Gary G.

“…The principal response criteria for many clinical trials involve time‐to‐event variables. Usual methods of analysis for this type of response criterion include…”
Get full text

Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter by Thompson, Ian M, Pauler, Donna K, Goodman, Phyllis J, Tangen, Catherine M, Lucia, M. Scott, Parnes, Howard L, Minasian, Lori M, Ford, Leslie G, Lippman, Scott M, Crawford, E. David, Crowley, John J, Coltman, Charles A

“…Almost 3000 men who received a placebo in the Prostate Cancer Prevention Trial and who never had a prostate-specific antigen (PSA) level of more than 4.0 ng…”
Get full text

Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them by Koch, Gary G., Tangen, Catherine M., Jung, Jin-Whan, Amara, Ingrid A.

“…Analysis of covariance is an effective method for addressing two considerations for randomized clinical trials. One is reduction of variance for estimates of…”
Get full text

Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study by Bukowski, R M, Tangen, C M, Peterson, R F, Taylor, S A, Rinehart, J J, Eyre, H J, Rivkin, S E, Fleming, T R, Macdonald, J S

“…The use of chemotherapy in patients with metastatic carcinoid tumors has been of limited value, and investigation of new agents is necessary. Previous reports…”
Get more information

Surgery for recurrent colon cancer : Strategies for identifying resectable recurrence and success rates after resection by GOLDBERG, R. M, FLEMING, T. R, TANGEN, C. M, MOERTEL, C. G, MACDONALD, J. S, HALLER, D. G, LAURIE, J. A

Get full text

Commentary: the ubiquity of prostate cancer: echoes of the past, implications for the present: "what has been will be again, what has been done will be done again; there is nothing new under the sun." ECCLESIASTES 1:9 by Thompson, Ian M, Lucia, M Scott, Tangen, Catherine M

Get full text

Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report by Moertel, C G, Fleming, T R, Macdonald, J S, Haller, D G, Laurie, J A, Tangen, C M, Ungerleider, J S, Emerson, W A, Tormey, D C, Glick, J H, Veeder, M H, Mailliard, J A

“…To determine the effectiveness of two adjuvant therapy regimens in improving surgical cure rates in stage III (Dukes stage C) colon cancer. Randomized,…”
Get full text

Association of African-American Ethnic Background With Survival in Men With Metastatic Prostate Cancer by Thompson, Ian M., Tangen, Catherine M., Tolcher, Anthony, Crawford, E. David, Eisenberger, Mario, Moinpour, Carol M.

“…Background: African-American men have earlier onset of prostate cancer, higher prostate-specific antigen (PSA) levels, more advanced stage at diagnosis, and…”
Get full text

Adjuvant continuous infusion 5-FU, whole-abdominal radiation, and tumor bed boost in high-risk stage III colon carcinoma: a Southwest Oncology Group Pilot study by Fabian, C, Giri, S, Estes, N, Tangen, C M, Poplin, E, Vogel, S, Goodwin, W, Rivkin, S, Fleming, T R, Macdonald, J S

“…Results of a combined modality adjuvant pilot program of low-dose continuous-infusion 5-fluorouracil, whole-abdominal radiation, and tumor bed boost in…”
Get more information

Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach. A Southwest Oncology Group study by Williamson, S K, Tangen, C M, Maddox, A M, Spiridonidis, C H, Macdonald, J S

“…We have conducted a Phase II trial in patients with metastatic gastric cancer utilizing low-dose continuous infusion 5-fluorouracil (5FU) and weekly cisplatin…”
Get more information

NONPARAMETRIC ANALYSIS OF COVARIANCE FOR HYPOTHESIS TESTING WITH LOGRANK AND WILCOXON SCORES AND SURVIVAL-RATE ESTIMATION IN A RANDOMIZED CLINICAL TRIAL by Tangen, Catherine M., Koch, Gary G.

“…Many clinical trials have time-to-event variables as principal response criteria. When adjustment for covariates is of some importance, the relative role of…”
Get full text